CEA-Leti (Grenoble, France) has received approximately $1.3 million in funding from bpifrance (Maison-Alfort, France) to accelerate preclinical development of a liver-cancer detection system called LipImage 815.
Related: Stenting plus PDT improves survival in late-stage liver cancer
The grant, awarded through bpifrance's Strategic Industrial Innovation (ISI) program, will speed the development of LipImage 815, including production and regulatory toxicity evaluation. It also supports the launch of Nano Innovation for Cancer (NICE), the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France.
Developed by CEA-Leti, LipImage 815 is a fluorescent imaging agent based on the Lipidots platform that uses lipid nanoparticles to carry a fluorescent substance to targeted cells and improve the effectiveness of diagnosis. It will be used to test for early stages of liver cancer.
Consisting of five public and private partners and led by BioAlliance Pharma, the NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.
For more information, please visit www.medicen.org/en.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!